If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||
![]() BioethicsVolume 18 Issue 4, Pages 361 - 378 Published Online: 19 Jul 2004 Journal compilation © 2010 Blackwell Publishing Ltd Journal of the International Association of Bioethics
Abstract | Full Text: PDF (Size: 81K) | Related Articles | Citation Tracking Ethical Implications of Pharmacogenetics – Do Slippery Slope Arguments Matter? Copyright Blackwell Publishing Ltd. 2004 ABSTRACT
Pharmacogenetics is a rapidly expanding area of research exploring the relationship between inter-individual genetic variation and drug response, with the goal of developing genetically optimised therapies. Slippery slope arguments claim that a particular action should be rejected (or supported) because it might be the first step onto a slippery slope leading to undesirable (or desirable) consequences. In this article, several slippery slope arguments relevant to the context of pharmacogenetics are evaluated under consideration of underlying reasons for their popularity. The author concludes that although the examined arguments are unconvincing as slippery slope arguments, they do matter in this context. While positive slippery slope arguments serve as a driving force to fuel the development of pharmacogenetics, their negative counterparts play an important role to sensitise policy makers and the public to potential problems. |